6 completed, 1 terminated. 5 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Terminated 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Inotek Pharmaceuticals Corporation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG trabodenoson 6.0% / latanoprost 0.005% QD, trabodenoson 3.0% / latanoprost 0.005% QD, trabodenoson 6.0% / latanoprost 0.0025% QD - Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT) | Phase 2 | Completed | Inotek Pharmaceuticals Corporation | 201 | 2016-08-19 | 2018-02-15 |
| Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma trabodenoson 4.5% BID, trabodenoson 6.0% QD, trabodenoson 3.0% QD - Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT) | Phase 3 | Completed | Inotek Pharmaceuticals Corporation | 303 | 2015-09-01 | 2016-12-06 |
| A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma Trabodenoson, Latanoprost, Timolol - Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT) | Phase 2 | Completed | Inotek Pharmaceuticals Corporation | 101 | 2013-08-01 | 2017-12-02 |
| A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma INO-8875, Placebo - Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Completed | Inotek Pharmaceuticals Corporation | 144 | 2010-05-01 | 2012-10-15 |
| Phase I Dose-Escalation Study to Evaluate Tolerability, Safety & PK of INO-8875 in Healthy Older-Adult Volunteers INO-8875, Placebo control - Health | Phase 1 | Completed | Inotek Pharmaceuticals Corporation | 70 | 2010-05-01 | 2012-04-30 |
| A Trial of INO-1001 in Patients Undergoing Heart Surgery That Involves Heart-lung Bypass INO-1001 - Heart Diseases, Postoperative Complications | Phase 2 | Terminated | Inotek Pharmaceuticals Corporation | 162 | 2005-10-01 | 2015-03-25 |
| A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention INO-1001 - Acute Myocardial Infarction | Phase 2 | Completed | Inotek Pharmaceuticals Corporation | 40 | 2004-01-01 | 2006-11-29 |
Glaucoma (4) · Glaucoma, Open-Angle (4) · Ocular Hypertension (4) · Heart Diseases (1) · Myocardial Infarction (1) · Postoperative Complications (1)
INO-8875 (4) · trabodenoson (3) · INO 1001 (2) · Latanoprost (2) · Timolol (2) · BID protein, human (1)
United States (7) · Israel (2) · Australia (1) · India (1)